MedCity News

JULY 2, 2024

The post Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi appeared first on MedCity News. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy.

Competition 125

Competition FDA Patients Biopharma 125

MedCity News

JANUARY 28, 2024

The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.

Competition 128

Competition Patients Manufacturing Biopharma 128

MedCity News

SEPTEMBER 6, 2024

The post Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas appeared first on MedCity News. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of its confirmatory study.

Competition 120

Competition FDA Patients Biopharma 120

MedCity News

SEPTEMBER 16, 2024

The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

Competition 125

Competition Pharma FDA Biopharma 125

MedCity News

NOVEMBER 14, 2022

These platforms need to replace traditional data management methods and workflows for biopharma companies and contract development and manufacturing organizations that seek competitive advantages. Cloud-based data management solutions help the industry meet its business and compliance challenges.

Biopharma 98

Biopharma Management Manufacturing Competition 98

MedCity News

FEBRUARY 6, 2024

However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

Competition 121

Competition Patients Biopharma Pharma 121

European Pharmaceutical Review

JUNE 8, 2023

A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.

Biopharma 98

Biopharma Government Training Education 98

MedCity News

APRIL 3, 2023

The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests. The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion.

Competition 113

Competition Biopharma 113

European Pharmaceutical Review

AUGUST 21, 2023

Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56

Biopharma 98

Biopharma Marketing Sales Medicine 98

MedCity News

JANUARY 22, 2024

If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.

Competition 116

Competition Pharmaceutical FDA Biopharma 116

MedCity News

NOVEMBER 7, 2023

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

Biopharma 135

Biopharma Competition FDA Pharma 135

PharmExec

JUNE 28, 2023

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

Biopharma 75

Biopharma Competition 75

European Pharmaceutical Review

DECEMBER 6, 2022

According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 percent from $3.45 trillion in Q2 2022 to $3.14 trillion in Q3 2022.

Biopharma 96

Biopharma Marketing Food and Drug Administration Sales 96

European Pharmaceutical Review

AUGUST 22, 2022

However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.

Biopharma 98

Biopharma Manufacturing Marketing Competition 98

MedCity News

AUGUST 17, 2022

The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer. Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule.

Competition 98

Competition Leads Pharmaceutical Patients 98

MedCity News

JULY 14, 2024

MiRecule, winner in the biopharma track of MedCity News’s Pitch Perfect startup competition, is now pursuing a Series A round of financing. RNA therapies developer miRecule is partnered with Sanofi on the development of a treatment for facioscapulohumeral muscular dystrophy, or FSHD.

Biopharma 110

Biopharma Competition Pharma 110

European Pharmaceutical Review

JULY 29, 2024

In Biopharma, where precision and accuracy are important, integrating robust processes is not just a necessity but a strategic imperative. Especially in complex ecosystems like the Biopharma ones, data integrity requires the collaboration of multiple departments. They serve as the foundation upon which data integrity is built.

Biopharma 83

Biopharma Manufacturing Ethics Competition 83

MedCity News

SEPTEMBER 12, 2022

As the biopharma space gets more competitive and the days of blockbuster drugs seem further in the rearview, biopharma companies are investing in digital to find new and innovative ways to differentiate themselves.

Biopharma 98

Biopharma Medical Competition Patients 98

PM360

AUGUST 24, 2023

As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.

Competition 98

Competition Marketing Healthcare Healthcare 98

MedCity News

DECEMBER 27, 2023

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

Competition 127

Competition Biopharma Pharma 127

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

Biopharma 59

Biopharma Competition Prescription Marketing 59

Pharmaceutical Technology

SEPTEMBER 11, 2023

With many biopharma companies outsourcing for manufacturing support, how can your organisation outpace the competition?

Competition 59

Competition Pharmaceutical manufacturing Manufacturing Biopharma 59

MedCity News

MAY 25, 2023

The competition saw 23 healthcare startups across biopharma, medical devices, and health tech geared for consumers/employers as well as payers/providers pitch their business plans to teams of investor judges.

Healthcare 98

Healthcare Healthcare Biopharma Competition 98

MedCity News

JUNE 16, 2023

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.

Competition 117

Competition FDA Biopharma Pharma 117

MedCity News

MAY 10, 2023

A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.

Competition 113

Competition FDA Biopharma Pharma 113

MedCity News

JULY 19, 2023

The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.

Competition 98

Competition Sales Marketing Biopharma 98

MedCity News

FEBRUARY 23, 2023

FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.

Competition 109

Competition FDA Patients Pharma 109

MedCity News

DECEMBER 13, 2022

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

Competition 109

Competition FDA Biopharma Pharma 109

Pharmaceutical Technology

JULY 29, 2022

As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. R&D ecosystem - Index score 6.54/10.

Biopharma 59

Biopharma Manufacturing Government Engineering 59

MedCity News

JANUARY 23, 2023

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Competition 98

Competition FDA Biopharma Pharma 98

MedCity News

JUNE 26, 2023

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

Competition 104

Competition FDA Biopharma Pharma 104

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

European Pharmaceutical Review

OCTOBER 26, 2022

With pharma/biopharma companies looking to select CDMO partners earlier than before, and in a competitive market, what approaches can be adopted? Included in this Guide to: The changing face of outsourcing. Here, EPR explores some recent trends and evolving strategies. Are you leveraging all the information from your QC data?

Biopharma 98

Biopharma Competition Pharma Management 98

Eversana Intouch

NOVEMBER 9, 2023

These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled. Not anymore. Despite this, most of the trade chatter around launch excellence assumes the launcher is big.

Pharma 105

Pharma Biopharma Competition Marketing 105

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

AUGUST 31, 2022

As the biopharmaceutical industry grows more competitive, so too does the need for effective supply chain management. This higher level of interdependence is due to the rapid growth rate of technology development within the biopharma and pharmaceutical industries.

Biopharma 52

Biopharma Manufacturing Pharmaceutical Marketing 52

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.

Competition 98

Competition Marketing Pharma Biopharma 98